Hegseth Wants Annual Testosterone Tests for Troops Over 30, The Pentagon is Preparing to Examine the Active-Duty Force.

The Pentagon is preparing to examine the active-duty force, turning testosterone levels into the latest measure in America’s evolving military-readiness strategy.

Defense Secretary Pete Hegseth announced Wednesday, July 15, that active-duty service members aged 30 and older will undergo annual screening for testosterone deficiency. Troops younger than 30 will be allowed to request the test voluntarily, while any recommended testosterone replacement therapy will remain optional. Uncement immediately drew attention because it places hormone screening inside the Pentagon’s wider campaign involving physical fitness, grooming, discipline and combat performance. Hegseth presented the program as preventive medicine designed to keep service members physically capable, mentally prepared, and medically supported throughout demanding military careers. What the new Pentagon policy requires

The testosterone screening will be added to the military’s Periodic Health Assessment, an annual review already required for service members. The assessment evaluates medical conditions, behavioral health, preventive care needs, and readiness for deployment. NS troops covered by the policy will not necessarily need a separate annual physical.

However, blood collection, repeat testing, and possible consultations with military healthcare providers could create additional steps for service members whose initial results fall outside established ranges. Hegseth said the purpose is to identify potential testosterone deficiency early and ensure troops can operate at their “absolute best.” He described the initiative as an effort to preserve natural capabilities, long-term health, and the biological foundation required to withstand the physical and psychological demands of military service.

The screening requirement and the treatment decision are separate. Testing will be mandatory for the covered age group, but testosterone replacement therapy will not be forced on anyone. Personnel advised to consider treatment may accept or reject the recommendation.

The Pentagon has not defined “low”

The most important details have not yet been released. The Pentagon has not said what testosterone level will trigger concern, which symptoms doctors will evaluate, or whether one low reading will automatically lead to a treatment recommendation. It has also not provided a detailed timeline for introducing the screening across the Army, Navy, Air Force, Marine Corps, and Space Force. Testosterone levels matter because testosterone levels can change according to the time of day, sleep quality, stress, illness, nutrition, medication, and other health factors.

Accurate testing is generally performed in the morning, and low results are commonly confirmed through a second blood test. The Endocrine Society recommends diagnosing hypogonadism only when a patient has symptoms associated with testosterone deficiency and consistently low laboratory results. The organization also advises against routinely screening otherwise healthy men in the general population. Personnel is not an ordinary civilian population. Their jobs may involve extreme physical demands, irregular sleep, combat stress, and repeated deployments. Those conditions could justify more intensive monitoring, but the Pentagon’s approach is still much broader than civilian medical guidelines typically recommend. Questions remain about women in uniform.

Another unresolved issue concerns female service members. Both men and women produce testosterone, although their normal ranges and clinical considerations differ significantly. Hegseth referred broadly to service members, but reports indicate the program appears primarily designed around testosterone deficiency in male troops.

Agon has not explained whether women will be tested under separate standards or how the program will address hormonal changes associated with menopause and perimenopause. It also has not clarified whether the same mandatory age threshold will apply regardless of sex.

Without detailed clinical guidance, commanders and military healthcare providers could face uncertainty over who qualifies for screening, what results require follow-up, and how sensitive medical information will be protected.

Why testosterone has become a readiness issue

Testosterone contributes to muscle mass, bone density, sexual function, red blood cell production, and mood. Levels often decline gradually as men age, particularly after their 30s or 40s.

A genuine deficiency can be associated with reduced libido, erectile dysfunction, loss of strength, mood changes, increased body fat, and decreased bone density. However, many symptoms blamed on low testosterone can also result from inadequate sleep, obesity, depression, chronic stress, medication side effects, or other medical conditions. Distinction will be critical in the military. A laboratory number alone does not provide a complete diagnosis, and treating every age-related decline could expose troops to medication they may not need.

The armed forces also have a complicated history with performance-enhancing hormones. After Navy SEAL candidate Kyle Mullen died during training in 2022, investigators discovered testosterone and other substances among his belongings. The case exposed concerns about unauthorized hormone and steroid use within elite training environments. Later, testing for anabolic steroids and other substances chemically connected to testosterone. Hegseth’s program now creates an authorized pathway for medically supervised treatment while insisting it is not intended to encourage artificial enhancement.

Treatment can help, but it requires supervision.

Testosterone replacement therapy can provide meaningful benefits for patients with properly diagnosed hypogonadism. Studies have found improvements in sexual function and modest gains in mood, muscle mass, and bone strength for some men.

The results are less convincing for fatigue, memory, and overall well-being. That means treatment may improve specific symptoms without delivering the sweeping transformation often promoted by wellness influencers and direct-to-consumer hormone clinics. Regulators have also revised their position as new evidence emerged. In 2025, the Food and Drug Administration removed a boxed warning suggesting testosterone products increased cardiovascular risks after reviewing a major safety trial.

However, the agency required class-wide warnings that testosterone can increase blood pressure. Patients receiving treatment may therefore require regular monitoring, especially if they have existing cardiovascular conditions. 2026, the FDA requested further labeling changes involving testosterone products and age-related hypogonadism. The change may make treatment easier to consider, but it does not transform testosterone into a universal anti-aging or performance medication. d policy now faces a practical test

Supporters may see the program as overdue attention to a condition that can affect older troops carrying the cumulative burden of deployments, injuries, disrupted sleep, and military stress. Early diagnosis could improve quality of life and help experienced personnel remain effective longer.

Critics will likely question the cost of screening an entire age group, the scientific justification for blanket testing, and the possibility that military culture could pressure troops toward treatment even when therapy is officially voluntary.

The program’s success will depend less on its forceful branding than on the clinical rules written beneath it. Clear thresholds, repeat testing, privacy protections, informed consent, and safeguards against unnecessary prescribing will determine whether it becomes useful preventive medicine or an expensive military experiment.

For now, the mandate is clear: active-duty service members aged 30 and older are entering a new era of annual hormone screening. What remains uncertain is how the Pentagon will define deficiency and demonstrate that testosterone testing makes America’s fighting force healthier, safer or more prepared for war.